Argenx
ARGX
#404
Rank
S$78.56 B
Marketcap
S$1,263
Share price
-0.55%
Change (1 day)
33.52%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2026 (TTM): S$20.50

According to Argenx 's latest financial reports the company's current EPS (TTM) is S$20.17. In 2025 the company made an earnings per share (EPS) of S$26.89 an increase over its 2024 EPS that were of S$17.76.

EPS history for Argenx from 2011 to 2026

Annual EPS

Year EPS Change
2026 (TTM)S$20.50-23.76%
2025S$26.8951.44%
2024S$17.76-369.77%
2023S-$6.58-60.46%
2022S-$16.6563.33%
2021S-$10.19-40.37%
2020S-$17.09183.47%
2019S-$6.03123.09%
2018S-$2.7054.93%
2017S-$1.7414.07%
2016S-$1.5313.05%
2015S-$1.35-36.34%
2014S-$2.13209.04%
2013S-$0.69-33.99%
2012S-$1.04185.59%
2011S-$0.36